Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sánchez-Borges (2008)
Clinical management of nonsteroidal anti-inflammatory drug hypersensitivityWAO Journal, 1
(Sánchez-BorgesMCapriles-HulettATolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactionsAnn Allergy Asthma Immunol2001220120410.1016/S1081-1206(10)62226-011570615)
Sánchez-BorgesMCapriles-HulettATolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactionsAnn Allergy Asthma Immunol2001220120410.1016/S1081-1206(10)62226-011570615Sánchez-BorgesMCapriles-HulettATolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactionsAnn Allergy Asthma Immunol2001220120410.1016/S1081-1206(10)62226-011570615, Sánchez-BorgesMCapriles-HulettATolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactionsAnn Allergy Asthma Immunol2001220120410.1016/S1081-1206(10)62226-011570615
(ChandrasekharanNVDaiHRoosKLEvansonNKTomsikJEltonTSSimmonsDLCOX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Cloning, structure and expressionProc Natl Acad Sci USA20022139261393110.1073/pnas.16246869912242329)
ChandrasekharanNVDaiHRoosKLEvansonNKTomsikJEltonTSSimmonsDLCOX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Cloning, structure and expressionProc Natl Acad Sci USA20022139261393110.1073/pnas.16246869912242329ChandrasekharanNVDaiHRoosKLEvansonNKTomsikJEltonTSSimmonsDLCOX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Cloning, structure and expressionProc Natl Acad Sci USA20022139261393110.1073/pnas.16246869912242329, ChandrasekharanNVDaiHRoosKLEvansonNKTomsikJEltonTSSimmonsDLCOX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Cloning, structure and expressionProc Natl Acad Sci USA20022139261393110.1073/pnas.16246869912242329
M. Sánchez-Borges, A. Capriles-Hulett, F. Caballero-Fonseca (2004)
The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity.Journal of investigational allergology & clinical immunology, 14 4
M. Sánchez-Borges, A. Capriles-Hulett, F. Caballero-Fonseca (2005)
Hypersensitivity Reactions to Weak COX InhibitorsAllergy & Clinical Immunology International-journal of The World Allergy Organization, 17
(Sánchez-BorgesMClinical management of nonsteroidal anti-inflammatory drug hypersensitivityWAO Journal20082293323283307)
Sánchez-BorgesMClinical management of nonsteroidal anti-inflammatory drug hypersensitivityWAO Journal20082293323283307Sánchez-BorgesMClinical management of nonsteroidal anti-inflammatory drug hypersensitivityWAO Journal20082293323283307, Sánchez-BorgesMClinical management of nonsteroidal anti-inflammatory drug hypersensitivityWAO Journal20082293323283307
R. Leung (1994)
Asthma, allergy and atopy in South-east Asian immigrants in Australia.Australian and New Zealand journal of medicine, 24 3
(Sánchez-BorgesMCapriles-HulettAAtopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivityAnn Allergy Asthma Immunol2000210110610.1016/S1081-1206(10)62748-210674573)
Sánchez-BorgesMCapriles-HulettAAtopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivityAnn Allergy Asthma Immunol2000210110610.1016/S1081-1206(10)62748-210674573Sánchez-BorgesMCapriles-HulettAAtopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivityAnn Allergy Asthma Immunol2000210110610.1016/S1081-1206(10)62748-210674573, Sánchez-BorgesMCapriles-HulettAAtopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivityAnn Allergy Asthma Immunol2000210110610.1016/S1081-1206(10)62748-210674573
M. Borges, A. Capriles-Hulett, F. Caballero-Fonseca, C. Perez (2001)
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 87 3
T. Warner, F. Giuliano, I. Vojnović, A. Bukasa, J. Mitchell, J. Vane (1999)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.Proceedings of the National Academy of Sciences of the United States of America, 96 13
Daniel Simmons, R. Botting, Philip Robertson, M. Madsen, J. Vane (1999)
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.Proceedings of the National Academy of Sciences of the United States of America, 96 6
(PicadoCThe role of cyclooxygenase in acetylsalicylic acid sensitivityAllergy Clin Immunol Int-J World Allergy Org2006215415710.1027/0838-1925.18.4.154)
PicadoCThe role of cyclooxygenase in acetylsalicylic acid sensitivityAllergy Clin Immunol Int-J World Allergy Org2006215415710.1027/0838-1925.18.4.154PicadoCThe role of cyclooxygenase in acetylsalicylic acid sensitivityAllergy Clin Immunol Int-J World Allergy Org2006215415710.1027/0838-1925.18.4.154, PicadoCThe role of cyclooxygenase in acetylsalicylic acid sensitivityAllergy Clin Immunol Int-J World Allergy Org2006215415710.1027/0838-1925.18.4.154
(Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFThe multiple faces of nonsteroidal anti-inflammatory drug hypersensitivityJ Inv Allergol Clin Immunol20042329334)
Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFThe multiple faces of nonsteroidal anti-inflammatory drug hypersensitivityJ Inv Allergol Clin Immunol20042329334Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFThe multiple faces of nonsteroidal anti-inflammatory drug hypersensitivityJ Inv Allergol Clin Immunol20042329334, Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFThe multiple faces of nonsteroidal anti-inflammatory drug hypersensitivityJ Inv Allergol Clin Immunol20042329334
(Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettATolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxibAnn Allergy Asthma Immunol20052343810.1016/S1081-1206(10)61282-315702813)
Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettATolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxibAnn Allergy Asthma Immunol20052343810.1016/S1081-1206(10)61282-315702813Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettATolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxibAnn Allergy Asthma Immunol20052343810.1016/S1081-1206(10)61282-315702813, Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettATolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxibAnn Allergy Asthma Immunol20052343810.1016/S1081-1206(10)61282-315702813
D. Quaratino, A. Romano, G. Papa, M. Fonso, F. Giuffreda, F. D'ambrosio, A. Venuti (1997)
Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 79 1
M. Sánchez-Borges, F. Caballero-Fonseca, A. Capriles-Hulett (2005)
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 94 1
Andrea Matucci, Paola Parronchi, A. Vultaggio, Oliviero Rossi, F. Brugnolo, Enrico Maggi, Sergio Romagnani (2004)
Partial safety of the new COX‐2 inhibitor rofecoxib in NSAIDs high sensitive patientsAllergy, 59
(SimmonsDLBottingRMRobertsonPMMadsenMLVaneJRInduction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugsProc Natl Acad Sci USA199923275328010.1073/pnas.96.6.327510077674)
SimmonsDLBottingRMRobertsonPMMadsenMLVaneJRInduction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugsProc Natl Acad Sci USA199923275328010.1073/pnas.96.6.327510077674SimmonsDLBottingRMRobertsonPMMadsenMLVaneJRInduction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugsProc Natl Acad Sci USA199923275328010.1073/pnas.96.6.327510077674, SimmonsDLBottingRMRobertsonPMMadsenMLVaneJRInduction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugsProc Natl Acad Sci USA199923275328010.1073/pnas.96.6.327510077674
(WarnerTDMitchellJACyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Proc Natl Acad Sci USA20022133711337310.1073/pnas.22254309912374850)
WarnerTDMitchellJACyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Proc Natl Acad Sci USA20022133711337310.1073/pnas.22254309912374850WarnerTDMitchellJACyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Proc Natl Acad Sci USA20022133711337310.1073/pnas.22254309912374850, WarnerTDMitchellJACyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Proc Natl Acad Sci USA20022133711337310.1073/pnas.22254309912374850
N. Chandrasekharan, H. Dai, K. Roos, N. Evanson, Joshua Tomsik, T. Elton, D. Simmons (2002)
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expressionProceedings of the National Academy of Sciences of the United States of America, 99
(QuaratinoDRomanoAPapaGDi FonsoMGiuffredaFPurelloD'AmbrosioFLong-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patientsAnn Allergy Asthma Immunol19972475010.1016/S1081-1206(10)63083-99236499)
QuaratinoDRomanoAPapaGDi FonsoMGiuffredaFPurelloD'AmbrosioFLong-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patientsAnn Allergy Asthma Immunol19972475010.1016/S1081-1206(10)63083-99236499QuaratinoDRomanoAPapaGDi FonsoMGiuffredaFPurelloD'AmbrosioFLong-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patientsAnn Allergy Asthma Immunol19972475010.1016/S1081-1206(10)63083-99236499, QuaratinoDRomanoAPapaGDi FonsoMGiuffredaFPurelloD'AmbrosioFLong-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patientsAnn Allergy Asthma Immunol19972475010.1016/S1081-1206(10)63083-99236499
A. Szczeklik (1990)
The cyclooxygenase theory of aspirin-induced asthma.The European respiratory journal, 3 5
(SzczeklikAThe cyclooxygenase theory of aspirin-induced asthmaEur Respir J199025885932115849)
SzczeklikAThe cyclooxygenase theory of aspirin-induced asthmaEur Respir J199025885932115849SzczeklikAThe cyclooxygenase theory of aspirin-induced asthmaEur Respir J199025885932115849, SzczeklikAThe cyclooxygenase theory of aspirin-induced asthmaEur Respir J199025885932115849
(MatucciAParronchiPVultaggioARossiOBrugnoloFMaggiEPartial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patientsAllergy200421133113410.1111/j.1398-9995.2004.00532.x15355480)
MatucciAParronchiPVultaggioARossiOBrugnoloFMaggiEPartial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patientsAllergy200421133113410.1111/j.1398-9995.2004.00532.x15355480MatucciAParronchiPVultaggioARossiOBrugnoloFMaggiEPartial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patientsAllergy200421133113410.1111/j.1398-9995.2004.00532.x15355480, MatucciAParronchiPVultaggioARossiOBrugnoloFMaggiEPartial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patientsAllergy200421133113410.1111/j.1398-9995.2004.00532.x15355480
M. Sánchez-Borges, F. Caballero-Fonseca, A. Capriles-Hulett (2005)
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 95 2
(Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettASafety of etoricoxib, a new cyclooxygenase-2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedemaAnn Allergy Asthma Immunol2005215415810.1016/S1081-1206(10)61205-716136765)
Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettASafety of etoricoxib, a new cyclooxygenase-2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedemaAnn Allergy Asthma Immunol2005215415810.1016/S1081-1206(10)61205-716136765Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettASafety of etoricoxib, a new cyclooxygenase-2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedemaAnn Allergy Asthma Immunol2005215415810.1016/S1081-1206(10)61205-716136765, Sánchez-BorgesMCaballero-FonsecaFCapriles-HulettASafety of etoricoxib, a new cyclooxygenase-2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedemaAnn Allergy Asthma Immunol2005215415810.1016/S1081-1206(10)61205-716136765
(Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFHypersensitivity reactions to weak COX inhibitorsAllergy Clin Immunol Int-J World Allergy Org20052586310.1027/0838-1925.17.2.58)
Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFHypersensitivity reactions to weak COX inhibitorsAllergy Clin Immunol Int-J World Allergy Org20052586310.1027/0838-1925.17.2.58Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFHypersensitivity reactions to weak COX inhibitorsAllergy Clin Immunol Int-J World Allergy Org20052586310.1027/0838-1925.17.2.58, Sánchez-BorgesMCapriles-HulettACaballero-FonsecaFHypersensitivity reactions to weak COX inhibitorsAllergy Clin Immunol Int-J World Allergy Org20052586310.1027/0838-1925.17.2.58
M. Sánchez-Borges (2008)
Clinical Management of Nonsteroidal Anti-inflammatory Drug HypersensitivityThe World Allergy Organization Journal, 1
T. Warner, J. Mitchell (2002)
Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?Proceedings of the National Academy of Sciences of the United States of America, 99
M. Sánchez-Borges, A. Capriles-Hulett (2000)
Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 84 1
C. Picado (2006)
The Role of Cyclooxygenase in Acetylsalicylic Acid SensitivityAllergy & Clinical Immunology International-journal of The World Allergy Organization, 18
(WarnerTDGiulianoFVoinovicIBukasaAMitchellJAVaneJRNonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysisProc Natl Acad Sci USA199927563756810.1073/pnas.96.13.756310377455)
WarnerTDGiulianoFVoinovicIBukasaAMitchellJAVaneJRNonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysisProc Natl Acad Sci USA199927563756810.1073/pnas.96.13.756310377455WarnerTDGiulianoFVoinovicIBukasaAMitchellJAVaneJRNonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysisProc Natl Acad Sci USA199927563756810.1073/pnas.96.13.756310377455, WarnerTDGiulianoFVoinovicIBukasaAMitchellJAVaneJRNonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysisProc Natl Acad Sci USA199927563756810.1073/pnas.96.13.756310377455
EDITORIAL ‘‘United Airways Disease’’ and Phenotypic Peculiarities of Respiratory Allergy in Immigrants Carlo Lombardi, Giovanni Passalaqua, and Giorgio Walter Canonica Abstract: Allergy is the result of a complex interaction between genetic background and environmental factors, including exposure to allergens and lifestyle. Migration is a process that involves many radical changes in the environment, including diet, pollutants, allergens, different housing conditions, and patterns of infections. Thus, studies in immigrants may provide important information about the role of environmental factors in the development of allergic respiratory diseases. Several studies addressed this aspect and consistently found that migrants develop allergies at different rates from the local population, and very often the symptoms appear with a delay of 3 to 5 years after migration. More recent data showed that the severity of allergic diseases is greater in migrants, and that usually the onset is with associated asthma and rhinitis. The immigration model strongly suggests that environmental factors overcome the genetic background, and that the clinical phenotype of respiratory allergy in migrants has some peculiarities. Key Words: asthma, rhinitis, allergy, immigration, migrants espiratory allergy (ie, rhinitis and asthma) has a high prevalence and, at least for rhinitis, Rthe prevalence is constantly increasing worldwide. Currently,
World Allergy Organization Journal – Wolters Kluwer Health
Published: Feb 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.